BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24500882)

  • 21. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer.
    Bristol JA; Schlom J; Abrams SI
    Cell Immunol; 1999 May; 194(1):78-89. PubMed ID: 10357883
    [TBL] [Abstract][Full Text] [Related]  

  • 22. T cells bearing anti-CD19 and/or anti-CD38 chimeric antigen receptors effectively abrogate primary double-hit lymphoma cells.
    Mihara K; Yoshida T; Takei Y; Sasaki N; Takihara Y; Kuroda J; Ichinohe T
    J Hematol Oncol; 2017 Jun; 10(1):116. PubMed ID: 28595585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD19-targeted CAR regulatory T cells suppress B cell pathology without GvHD.
    Imura Y; Ando M; Kondo T; Ito M; Yoshimura A
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32525846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting of antigens to B cells augments antigen-specific T-cell responses and breaks immune tolerance to tumor-associated antigen MUC1.
    Ding C; Wang L; Marroquin J; Yan J
    Blood; 2008 Oct; 112(7):2817-25. PubMed ID: 18669871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.
    Cheadle EJ; Hawkins RE; Batha H; O'Neill AL; Dovedi SJ; Gilham DE
    J Immunol; 2010 Feb; 184(4):1885-96. PubMed ID: 20089697
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells.
    Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS
    Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
    Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
    Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.
    Riddell SR; Sommermeyer D; Berger C; Liu LS; Balakrishnan A; Salter A; Hudecek M; Maloney DG; Turtle CJ
    Cancer J; 2014; 20(2):141-4. PubMed ID: 24667960
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Transfer of IFNgamma-depleted CD4(+) T cells together with CD8(+) T cells leads to rejection of murine kidney sarcoma in mice.
    Klugewitz K; Scheffold A; Radbruch A; Hamann A
    Int J Cancer; 2000 Sep; 87(5):673-9. PubMed ID: 10925361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies.
    Bogen B; Munthe L; Sollien A; Hofgaard P; Omholt H; Dagnaes F; Dembic Z; Lauritzsen GF
    Eur J Immunol; 1995 Nov; 25(11):3079-86. PubMed ID: 7489746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
    Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
    J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunization with a lentiviral vector stimulates both CD4 and CD8 T cell responses to an ovalbumin transgene.
    Rowe HM; Lopes L; Ikeda Y; Bailey R; Barde I; Zenke M; Chain BM; Collins MK
    Mol Ther; 2006 Feb; 13(2):310-9. PubMed ID: 16275163
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of an artificial antigen-presenting cell to propagate cytolytic CD19-specific T cells.
    Numbenjapon T; Serrano LM; Singh H; Kowolik CM; Olivares S; Gonzalez N; Chang WC; Forman SJ; Jensen MC; Cooper LJ
    Leukemia; 2006 Oct; 20(10):1889-92. PubMed ID: 17041638
    [No Abstract]   [Full Text] [Related]  

  • 35. Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.
    Niethammer AG; Xiang R; Ruehlmann JM; Lode HN; Dolman CS; Gillies SD; Reisfeld RA
    Cancer Res; 2001 Aug; 61(16):6178-84. PubMed ID: 11507070
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens.
    Van Nuffel AM; Tuyaerts S; Benteyn D; Wilgenhof S; Corthals J; Heirman C; Neyns B; Thielemans K; Bonehill A
    J Immunol Methods; 2012 Mar; 377(1-2):23-36. PubMed ID: 22269772
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effector functions of T cells are dependent on in vivo priming and restricted T-cell receptor expression.
    Lüking C; Kronenberger K; Frankenberger B; Nössner E; Röcken M; Mocikat R
    Int J Cancer; 2008 May; 122(10):2280-5. PubMed ID: 18224683
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gene-edited healthy donor CAR T cells show superior anti-tumour activity compared to CAR T cells derived from patients with lymphoma in an in vivo model of high-grade lymphoma.
    Graham CE; Jozwik A; Quartey-Papafio R; Ioannou N; Metelo AM; Scala C; Dickson G; Stewart O; Almena-Carrasco M; Peranzoni E; Ramsay AG; Patten PEM; Pertel T; Farzaneh F; Dupouy S; Pepper A; Benjamin R
    Leukemia; 2021 Dec; 35(12):3581-3584. PubMed ID: 34145373
    [No Abstract]   [Full Text] [Related]  

  • 39. Regression of a murine gammaherpesvirus 68-positive b-cell lymphoma mediated by CD4 T lymphocytes.
    Robertson KA; Usherwood EJ; Nash AA
    J Virol; 2001 Apr; 75(7):3480-2. PubMed ID: 11238875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.
    Turtle CJ; Hanafi LA; Berger C; Hudecek M; Pender B; Robinson E; Hawkins R; Chaney C; Cherian S; Chen X; Soma L; Wood B; Li D; Heimfeld S; Riddell SR; Maloney DG
    Sci Transl Med; 2016 Sep; 8(355):355ra116. PubMed ID: 27605551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.